Buy Verizon (VZ) stock for your dividend and 5G future?


TipRanks

These 3 penny stocks have a massive upside potential, Cowen says

It is a mixed bag when it comes to opinions on penny stocks. These tickers trade for less than $ 5 per share, not dividing Wall Street like the others; Market watchers either love them or hate them. The appeal is easy to understand. First and foremost, you’re more bang for your buck. On top of that, changing hands for bargain prices of shares, even what seems like miniscule share price appreciation can translate to a monthly percentage gain. However, for some, the risk is too much to ignore. When you look under the hood of these low-priced names, you may find very real problems, such as bad fundamentals or emerging headwinds. So, how should investors keep the stock of money going from the rags to the rich? Considering the prosecution, we wanted to take a look at the three-page stock that was gaining love from the prosecution, namely analysts at investment firm Cowen. According to the firm, all three may climb in the coming year. Using TipRanks’ database, we learned why Cowen analysts have accelerated the table despite the risks. Nino Therapeutics (NEOS) is developing and commercializing innovative products, Neos Therapeutics seeks to make a significant change in the lives of patients with Attitude Deficit Hyperactivity Disorder (ADHD) and other central nervous system (CNS) conditions. While the name has struggled in the past, Cowen believes that at $ 0.47, it’s time to snap up stocks. For the firm, analyst Ken Cassiatator acknowledges the momentum that was being driven by the company’s amphetamine-Adzen-XR-ODT. ADHD, and treatment based for cotempala, with its methylphenidate-based CNS stimulant also designed for ADHD, have slowed due to the epidemic. However, based on recent prescription trends, analysts are seeing signs of recovering acceleration behind school (via video / classroom) in Q4. Disclosing this, Cacciatore said, “We are confident that management is taking over. Right steps with strategic reforms that aim to improve profitability per se with more targeted prescriber base focus and newco-pay support / fulfillment programs (RX Connect) seems to benefit from more rapid adoption. And given that RX Connect appears to be its initial success with the reduction plan and Salesforce reorganization, we believe Neos could reach profitability by 2022 . “Net revenue per pack for AdGen and Cotepla appears to grow 6-year-over-year to $ 128, Cacciatore argues, company’s efforts are off.” Again, we believe these data points are better Reflect the commercial approach, and the effectiveness of the company’s Neos RX Connect pharmacy program that simplifies more complex prescription fulfillment and co-payment assistance than before, “he commented. About RX Connect, physician patient call-back Can prescribe prescriptions for Cotempla and Adzenys without worrying. According to this, 30% of prescriptions are currently fulfilled through this program, and after the addition of several large regional pharmacy chains, the total number of participating pharmacies in June, compared to 800 at the end of Q1 in June Was around 900. The fact that NEOS is the only company that has both methylphenate and amphetamine as an alternative dosage formulation product for the treatment of ADHD is enough to make it a stand-out in the opinion of Cashytorol. Calling Cotempla “the perfect complement to Adgenis”, he said that each property covers half of the large stimulant market. The analyst stated, “Adgenis XR-ODT has experienced impressive prescription growth over the past year, and now has ADHD’s take on Pfizer’s market-leading Quillivant XR as its new-to-brand market share The alternative dosage form was relegated to No. 1 position. ”In addition, NEOS offers Adzenys ER, an extended-release liquid stimulant product for ADHD. This product is amphetanes-based such as Adgenis XR-ODT, But there is an alternate dose for patients who do not like tablets or capsules. Cacciatore points out that success has already been demonstrated as a liquid alternative dose because Pfizer’s Quillivant XR has $ 100 in 2017 annual sales. Has grossed over million. To this end, Cacciatore rated NEOS an outperform (ie buy) with an $ 8 price target. Should the target be met, a twelve-month gain in size of 1,604% could be in store. (To see Cacciatore’s track record, click here) Now of the rest of the street Moving on, 3 Buys and No Holds or Sells have not been published in the last three months. Therefore, NEOS has a strong Buy Consensus rating. At $ 8.33, the average price target is more aggressive than Cacciatore and means 1674% upside potential. (See NEOS stock analysis on TipRank) Dynavax Technologies (DVAX) develops vaccines to protect Dynavax populations, bringing toll-like receptor (TLR) biology and cutting-edge adjuvant technology to the table. Thanks to its promising pipeline and $ 4.30 share price, Cowen believes investors should join the action. Should the firm reap the benefits, 5-Star analyst Phil Nadeau cites Heplicev as a key component of his sharp thesis. The product is an HBV vaccine that has been shown to be more effective than the HBV vaccine in other Phase 3 trials. Based on the remarks of the firm’s advisors, they argue that the assets may occupy a significant share in the worldwide market of more than $ 500 million for adult HBV vaccines. To contribute to Nadeau’s optimistic stance, DVAX has agreed to several efforts to locate CIPG 1018. Helpful in heplice may improve the efficacy of other vaccines. In September, DVAX announced its supply agreement with Valneva, which would produce 190 million doses in five years of Valneva’s COVID-19 vaccine candidate VLA2001. This vaccine is an inactivated virus against the SARS-CoV-2 virus, and will incorporate the CpG 1018 helper of DVAX. The clinical trial is expected to kick in by the YE, with approval potentially coming in at 2H21. In addition, the UK government has secured a supply of 60 million doses for € 470 million, and an option for another 130 million doses for around € 900 million. It has already stated that it wants to make CpG 1018 a widely used accessory, and is making rapid progress in implementing it, Nadeau says. He said the deal is in line with this strategy, and “in some ways represents the next step.” He added, “The supply agreement is notable because it helps to demonstrate to economists that it can partially bring about the successful development of vaccines.” According to the company’s guidance, CpG 1018 can capture 15–30% of economics when used in partner vaccines. “Although management has not disclosed the exact economics in the Walneva cooperation, we believe they are consistent with DVX’s guidance and suspect they are towards the middle of the range,” Nadeau commented. “In our opinion the DVX is not too short for the capacity of the heaplice. And the CpG 1018 subsidiary,” concluded Nadue. It should come as no surprise, then, that Nadeau sides with the bull. With an outperform (ie buy) rating, he targets a price of $ 20 on the stock, indicating 370% upside potential. (To see Nadeau’s track record, click here) Other analysts echo Nadeau’s sentiment. 3 buys and no hold or sell add to a strong buy consensus rating. Inverted capacity comes in at 276%, with an average price target of $ 16. (See DVAX stock analysis on TipRank) La Jolla Pharmaceutical (LJPC) Last but not least we have La Jolla Pharmaceutical, which develops innovative treatments for life-threatening diseases with significant unchanged need. Given his impressive technique, Cowen sees his $ 4 share price as presenting an attractive entry point. Enlist Phil Nadeau, who also covers DVX for the firm, highlights the preparation of a patent for angiotensin II, a naturally occurring hormone peptide, Giapreza, LJPC’s first commercial product. , As a point of power. Angiotensin II is a potent vasoconstrictor and a major regulator of blood pressure. The launch has been stony, with epidemics severely hurting the area inside the hospital. That said, Nadeo remains optimistic. “, Our consultants feel that CRH needs new vasopressors, and so we hope Giapreza can ramp up over time to become a meaningful product,” he explained. In July, LPC acquired tetrapase, giving Xerava the authority, a novel fluorescein antibacterial designed for the treatment of complex intra-abdominal infections. Even though the use of therapy was most affected by COVID-19, Nadeau has high expectations for the product. Nadeau argues that LJPC will be able to leverage its existing infrastructure and promote Zerwa, with only minimal expenditure expected. Many competitors, the market for antibiotics used to treat intra-abdominal infections is large – patients with appendicitis contribute more than 1 million hospitalizations each year in the US alone, thus, with promotion, Zerwa Should continue to grow, “the analyst said. To date, Nadeau invested $ 15 million in Zerwa revenue in 2021. The figure reached $ 60 million in 2024. All of this, Nadeau said,” is modest. Businesses with enterprise value, La Jolla’s valuation is not commercialized. “Keeping the above in mind, Nadeau has given LJPC an outperform (ie buy) rating, with a $ 20 price target. This target reflects his confidence in LJPC’s ability to climb 402% more over the next year. What does Rest Street have to say? When it comes to other analyst activity, it has become relatively quiet. 2 purchases and no holds or sale have been issued in the last three months. Therefore, LJPC gets a Moderate Buy Consensus Rating. Based on an average price target of $ 14, shares could skyrocket 251% over the next year. (See LJPC Stock Analysis at TipRank) To discover good ideas for penny stock trading at attractive valuations, TipRank’s Best Stocks to Buy, a newly launched tool that equips all of TipRanks’ equity insights. Unites the disclaimer: The opinions expressed in this article are only those of select analysts. Content is to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Leave a Reply